Basic Information
| LncRNA/CircRNA Name | AC023824.1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | RNA-seq |
| Sample | LUAD tissues |
| Expression Pattern | differential expression |
| Function Description | Combined DNA methylation and gene expression survival analysis revealed that 4 lncRNAs (AC023824.1, AF186192.1, LINC01354 and WASIR2) and 8 mRNAs (S1PR1, CCDC181, F2RL1, EFS, KLHDC9, MPV17L, GKN2, ITPRIPL1) might act as independent biomarkers for the prognosis of LUAD. |
| Pubmed ID | 31558162 |
| Year | 2019 |
| Title | Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers. |
External Links
| Links for AC023824.1 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |